Avaxia is a leader in the growing field of gut-targeted therapeutics - orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia's lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is using its proprietary oral antibody platform to develop gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/18/12 | $6,400,000 | Series B |
Beacon Angels Beta Fund Boston Harbor Angels Cherrystone Angels Golden Seeds Granite State Angels Keiretsu Forum Maine Angels North Country Angels | undisclosed |
| 06/07/13 | $11,400,000 | Series B |
AbbVie Biotech Ventures Ariel Savannah Angel Partners Beacon Angels Boston Harbor Angels Cherrystone Angels Golden Seeds Launchpad Venture Group Mass Medical Angels Tech Coast Angels | undisclosed |
